Strug, Lisa J

Published purpose

This Priority Announcement (PA) is led by the Institute of Circulatory and Respiratory Health (CIHR-ICRH) in partnership with Cystic Fibrosis Canada. The CIHR-ICRH has the broad mandate of supporting research on the heart, lung, brain (stroke), blood, blood vessels, critical and intensive care, and sleep. Cystic Fibrosis Canada has the mandate to act boldly for all Canadians living with cystic fibrosis so they can live longer, healthier, fuller lives. This Priority Announcement is focused on cystic fibrosis across the lifespan. The proposed research should inform the management of cystic fibrosis (CF) across the lifespan. • Examples include, but are not limited to: o Understanding the changing health issues of individuals with CF as they age o Understanding the long-term effects of medications (including CF transmembrane conductance regulators (CFTR) modulators) in CF over the lifespan o Understanding the impact of modulators on fetal development or early childhood o Understanding changes in treatments as people with CF age o Strategies to maintain and enhance lung health over the lifespan o Transitions from pediatric to adult CF care o Preventative strategies for cardiovascular and other complications • Research focusing on more than one (1) developmental or intergenerational period over the lifespan is encouraged. Examples include, but are not limited to: o one developmental period before and after age 18, or o different developmental periods across generations (e.g. biological parent and fetus or offspring), or o two (2) developmental periods in females related to puberty, child-bearing age and menopause. • Sex and gender consideration should be integrated as appropriate.